StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about GUTS. Only you ever see it.
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $1.00 | $0.95 | -4.60% | 5.1M |
| 05-15 | $0.93 | $0.86 | -7.50% | 2.8M |
| 05-18 | $0.88 | $0.81 | -8.36% | 2.2M |
| 05-19 | $0.80 | $0.82 | +1.82% | 1.1M |
| 05-20 | $0.84 | $0.92 | +9.82% | 1.7M |
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $93.00K | $90.00K | $76.00K |
Operating Income | $-96.82M | $-93.53M | $-68.32M | $-44.53M |
Net Income | $-140.95M | $-68.69M | $-43.72M | $-17.23M |
EPS (Diluted) | $-1.86 | $-1.62 | $-1.09 | $-0.57 |
Total Assets | $121.40M | $108.08M | $126.92M | $146.44M |
Total Liabilities | $111.94M | $79.65M | $76.60M | $75.68M |
Cash & Equivalents | $81.54M | $67.46M | $84.66M | $102.44M |
Free Cash Flow OCF − CapEx | $-90.89M | $-67.29M | $-50.02M | $-31.77M |
Shares Outstanding | 153.37M | 48.76M | 48.09M | 47.91M |
GUTS is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.